<DOC>
	<DOCNO>NCT00845533</DOCNO>
	<brief_summary>This open-label trial Burkina Faso assess pharmacokinetics antimalarial combination dihydroartemisinin/piperaquine ( DP , Duocotexcin ) child . Dihydroartemisinin-piperaquine promising candidate first-line therapy malaria . We hypothesize disposition pharmacokinetics DP alter child , alter efficacy and/or toxicity DP . We test hypothesis open-label trial Burkina Faso . The target population include resident , age 6 month 10 year Bobo-Dioulasso . Children present study clinic symptom suggestive malaria screen thick blood smear . Subjects meet selection criterion treatment efficacy treat follow 42 day . Pharmacokinetic sample DP occur select follow-up day .</brief_summary>
	<brief_title>Pharmacokinetics Dihydroartemisinin-Piperaquine Treatment Uncomplicated Malaria Children Burkina Faso</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Positive screen thick blood smear 2 . Fever ( &gt; 37.5ºC axillary ) history fever previous 24 hour 3 . Age ≥ 6 month 10 year 4 . Weight &gt; 5 kg 5 . Absence history serious side effect study medication 6 . No evidence concomitant febrile illness addition malaria 7 . No history antimalarial use previous two week 8 . P. falciparum monoinfection 9 . Parasite density 2000200,000/ul 10 . Provision informed consent ability participate 42day followup 1 . Danger sign evidence severe malaria 2 . Hemoglobin level &lt; 5.0 gm/dL</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>